查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014284

心臟生物标记市场：按生物标记类型、临床环境、应用和最终用户划分－2026-2032年全球市场预测

Cardiac Biomarker Market by Biomarker Type, Clinical Setting, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，心臟生物标记市场价值将达到 144.1 亿美元，到 2026 年将成长至 156.5 亿美元，到 2032 年将达到 270.9 亿美元，复合年增长率为 9.43%。

主要市场统计数据
基准年 2025 144.1亿美元
预计年份：2026年 156.5亿美元
预测年份 2032 270.9亿美元
复合年增长率 (%) 9.43%

对塑造心臟生物标记诊断未来的不断变化的临床需求和技术期望进行基本概述。

心臟生物标记领域处于临床需求与技术创新交会点，其发展动力源自于对更快、更准确诊断和更完善的患者照护流程的需求。随着临床日益重视急性心臟疾病的早期检测以及对更精准风险分层的需求，生物标记检测正从辅助手段跃升为急诊慢性心臟疾病诊疗的核心要素。因此，包括临床检查室、医院系统和诊断设备製造商相关人员正在重新思考其检测项目、工作流程和照护现场实施策略，以适应不断发展的临床方案。

这是一个关键的技术、临床和营运转折点，它正在加速创新，并改变心臟生物标记解决方案在医疗保健系统中的部署。

近年来，心臟生物标记的开发、检验和应用在诊疗路径中发生了变革性变化。高灵敏度免疫检测改变了诊断阈值，使得早期发现心肌损伤成为可能。这反过来又改变了急诊和门诊的临床诊疗流程。同时，分散式检查模式的普及挑战了传统的检查室为中心的模式，使患者能够在更接近诊疗路径的地方快速做出决策。这些结构性变化也影响采购、训练和报销等方面的考量。

对 2025 年美国贸易措施如何重塑心臟生物标记相关人员的筹资策略、供应弹性和营运连续性进行全面评估。

政策环境和贸易趋势为依赖跨境供应链获取试剂、仪器和耗材的製造商、经销商和临床检查室带来了新的考虑。 2025年实施的关税调整和贸易措施迫使各机构重新评估筹资策略、库存管理和供应商多元化。因此，采购团队越来越重视供应弹性、在地采购和合约柔软性，以确保关键诊断方法的持续供应。

细分市场主导的洞察表明，每种类型的生物标记、临床环境、应用和最终用户都需要单独的开发、监管和商业化途径。

详细的細項分析揭示了不同生物标记类型、临床环境、应用和最终用户群体之间的不同趋势，这些趋势应指南针对性策略。生物标记特异性趋势包括：在高灵敏度检测方法的推动下，肌钙蛋白持续受到临床关注；脑钠肽 (BNP) 和 N 端脑钠肽前体 (NT-proBNP) 在心臟衰竭的管理和预后监测中仍然发挥重要作用。肌酸激酶 (CK) MB 和肌红蛋白在特定诊断环境中继续发挥重要作用，尤其是在多重检测方法中，连续测量结果为临床决策提供了基础。

区域策略差异：美洲、欧洲、中东和非洲以及亚太地区各自面临独特的临床和监管要求以及供应链挑战。

区域趋势对技术应用、临床实务和供应链设计有显着影响。在美洲，随着人们对成熟检测网络和分散式检查模式的兴趣日益浓厚，医疗系统优先考虑在急诊护理中快速决策，并广泛采用高灵敏度检测方法。该地区的相关人员通常优先考虑与大规模医疗资讯系统集成，并遵守影响检测性能预期的监管标准。

本报告探讨了成熟的检测服务提供者和敏捷的创新者如何利用临床证据、製造和伙伴关係，在竞争与合作的趋势中获得诊断的重要性。

心臟生物标记诊断领域的竞争格局既体现在成熟的检测服务供应商，也体现在寻求透过提升分析能力、整合工作流程和实现功能分散化来实现临床差异化的敏捷创新者。大型成熟公司通常利用其广泛的分销网络、多年的临床检验数据和整合平台来维持大规模医疗系统和参考实验室的信任。同时，规模较小的公司和新参与企业则专注于高灵敏度检测、照护现场设备以及与临床试验网络的合作，以累积证据支持其在急诊和门诊环境中的应用。

製造商、检查室和医疗保健领导者面临的可操作的策略挑战，即如何协调临床检验、供应链弹性和数位整合，以实现永续部署。

产业领导企业可以透过将产品蓝图与临床工作流程相契合，并增强其价值链的韧性以抵御政策和物流方面的干扰，从而加速价值创造。优先考虑与电子健康记录和决策支援系统的互通性，可以减少临床应用障碍，并提升生物标记结果的实际价值。此外，投资于能够证明其在关键应用情境（特别是急性冠状动脉症候群、郁血性心臟衰竭和心肌梗塞的治疗路径）中效用的临床检验研究，将极大地增强临床医生的信心和保险公司的认可度。

我们采用透明的混合方法，结合对临床医生的访谈、文献综述、监管分析和情境评估，以确保我们的研究结果在临床和操作上的严谨性。

本次高阶主管分析的背景研究结合了多方面的证据收集以及结构化的定性和定量方法，以确保得出可靠且可重复的结论。主要研究包括对临床实验室部门负责人、心臟科医生、循环系统采集经理和行业高管的访谈，以了解关于检测性能、检体整合和推广障碍的最新观点。次要研究则利用了同行评审的临床文献、监管指导文件和公开的临床试验註册信息，以支持关于临床效用和分析性能特征的论点。

简要概述临床创新、供应链韧性和有针对性的证据策略如何决定心臟生物标记引入的成功。

总之，心臟生物标记诊断正处于关键的十字路口，透过检测技术创新、数位化整合和供应链策略的交汇，重塑着临床实践。高灵敏度检测和分散式检查模式正在缩短诊断时间，并加快治疗路径。同时，不断变化的贸易格局凸显了札根本地的供应链韧性和策略伙伴关係关係的重要性。此外，生物标记类型、临床环境、应用和最终用户等细分市场的具体因素，也强调了製定个人化开发和商业化策略的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按生物标记类型分類的心臟生物标记市场

  • BNP 和 NT-proBNP
  • 肌酸激酶（CK）MB
  • 肌红蛋白
  • 肌钙蛋白

第九章：依临床环境分類的心臟生物标记市场

  • 临床试验
  • 即时检测

第十章：心臟生物标记市场：依应用领域划分

  • 诊断
    • 急性冠状动脉症候群
    • 郁血性心臟衰竭
    • 心肌梗塞
  • 预后
  • 风险评估

第十一章：心臟生物标记市场：依最终用户划分

  • 诊断检查室
  • 医院和诊所
  • 研究机构

第十二章 心臟生物标记市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：心臟生物标记市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 心臟生物标记市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国心臟生物标记市场

第十六章：中国心臟生物标记市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Abcam plc
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • Epitope Diagnostics Inc.
  • F. Hoffmann-La Roche AG
  • Fujirebio Diagnostics Inc.
  • Guangzhou Wondfo Biotech Co., Ltd.
  • Hologic Inc.
  • Johnson & Johnson Services, Inc.
  • Life Diagnostics, Inc.
  • LSI Medience Corporation
  • Meridian Bioscience, Inc.
  • Myriad RBM Inc.
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
  • Quidel Corporation
  • QuidelOrtho Corporation
  • Randox Laboratories Limited
  • Sekisui Medical Co., Ltd.
  • Siemens Healthineers AG
  • Singulex, Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Tosoh Corporation
  • Trinity Biotech plc
Product Code: MRR-433AB1DC288D

The Cardiac Biomarker Market was valued at USD 14.41 billion in 2025 and is projected to grow to USD 15.65 billion in 2026, with a CAGR of 9.43%, reaching USD 27.09 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.41 billion
Estimated Year [2026] USD 15.65 billion
Forecast Year [2032] USD 27.09 billion
CAGR (%) 9.43%

Foundational overview of evolving clinical demands and technological expectations shaping the future trajectory of cardiac biomarker diagnostics

The cardiac biomarker landscape sits at the intersection of clinical necessity and technological innovation, driven by the need for faster, more accurate diagnostics and improved patient pathways. Rising clinical emphasis on early detection of acute cardiac events and the demand for more precise risk stratification have elevated biomarker testing from a supportive role to a central component of emergent and chronic cardiac care. As a result, stakeholders across clinical laboratories, hospital systems, and diagnostic manufacturers are re-evaluating assay portfolios, operational workflows, and point-of-care deployment strategies to align with evolving clinical protocols.

Moreover, regulatory scrutiny and quality expectations have heightened, prompting assay developers and clinical laboratories to prioritize analytical sensitivity, specificity, and reproducibility. Emerging platforms emphasize integration with electronic health records and decision support tools, enabling clinicians to interpret biomarker results in the context of real-time patient data. In this environment, strategic decisions about technology adoption, partnerships, and clinical validation become decisive factors in differentiating offerings and delivering measurable improvements in patient outcomes. Consequently, leaders must balance clinical utility, operational feasibility, and regulatory readiness when shaping future investments.

Key technological, clinical, and operational inflection points that are accelerating innovation and altering health system adoption of cardiac biomarker solutions

Recent years have produced transformative shifts that are redefining how cardiac biomarkers are developed, validated, and used in care pathways. High-sensitivity immunoassays have altered diagnostic thresholds and enabled earlier detection of myocardial injury, which in turn changes clinical algorithms for emergency departments and ambulatory care. Simultaneously, the proliferation of decentralized testing models is challenging traditional laboratory-centric paradigms by enabling rapid decision-making closer to the patient. These structural changes ripple across procurement, training, and reimbursement considerations.

Concurrently, digital integration and advanced analytics have begun to amplify the value of biomarker data. Machine learning models increasingly assist in interpreting serial biomarker measurements alongside clinical parameters, thereby improving diagnostic accuracy and risk stratification. The expanding role of multiplexed and panel-based testing introduces both opportunity and complexity, requiring cross-disciplinary validation and harmonized laboratory standards. In response, manufacturers and clinical leaders are pursuing partnerships to streamline workflows, validate clinical utility, and ensure that innovations translate into practical, deployable solutions that enhance care delivery.

Comprehensive assessment of how 2025 United States trade measures are reshaping procurement strategies supply resilience and operational continuity for cardiac biomarker stakeholders

The policy environment and trade dynamics have introduced new considerations for manufacturers, distributors, and clinical laboratories that rely on cross-border supply chains for reagents, instruments, and consumables. Tariff changes and trade measures implemented in 2025 have compelled organizations to revisit sourcing strategies, inventory management, and supplier diversification. As a result, procurement teams have intensified focus on supply resilience, component localization, and contractual flexibility to maintain continuity of critical assay availability.

In practice, these tariff-driven pressures influence cost structures and supplier selection without altering clinical evidence requirements. Laboratories and health systems have responded by increasing their emphasis on validated alternate suppliers, longer lead-time planning, and tighter inventory controls for high-use reagents. For manufacturers, the tariff landscape has accelerated interest in regional manufacturing partnerships and qualification of additional contract manufacturers to minimize exposure to policy volatility. Looking ahead, firms that proactively adapt procurement networks and that invest in redundant supply paths will better preserve clinical operations and market responsiveness under fluctuating trade conditions.

Segment-driven intelligence revealing how biomarker types clinical settings applications and end users demand tailored development regulatory and commercialization pathways

A nuanced view of segmentation uncovers differential dynamics across biomarker type, clinical setting, application, and end user that should guide targeted strategies. Biomarker-specific developments include sustained clinical emphasis on troponins driven by high-sensitivity assays, while BNP and NT-proBNP continue to command attention for heart failure management and prognostic monitoring. Creatine Kinase (CK) MB and myoglobin retain roles in specific diagnostic contexts and as part of multiplexed approaches, particularly where serial measurements inform clinical decisions.

Clinical setting distinctions matter because laboratory testing remains the backbone for high-throughput, standardized analysis, whereas point of care testing delivers rapid, on-site results that shift emergency and acute care workflows. Application-driven priorities vary by use case: diagnosis requires rapid analytic turnaround and stringent clinical validation across acute coronary syndrome, congestive heart failure, and myocardial infarction pathways; prognosis demands reproducibility and longitudinal consistency; and risk assessment integrates biomarker results with clinical models to guide preventative strategies. End user profiles also dictate go-to-market tactics, as diagnostic laboratories focus on throughput and standardization, hospitals and clinics prioritize integrated workflows and interpretive support, and research institutes emphasize novel biomarker discovery and translational validation. Consequently, product development, commercial outreach, and clinical validation programs should align with the unique needs and decision criteria of each segment to maximize clinical adoption and operational fit.

Regional strategic differentiation highlighting how the Americas Europe Middle East & Africa and Asia-Pacific each present distinct clinical regulatory and supply chain imperatives

Regional patterns exert a significant influence on technology adoption, clinical practice, and supply chain design. In the Americas, health systems emphasize rapid acute care decision-making and broad deployment of high-sensitivity assays, supported by established laboratory networks and growing interest in decentralized testing models. Stakeholders in this region typically prioritize integration with large health information systems and adherence to regulatory standards that drive assay performance expectations.

Europe, Middle East & Africa exhibits heterogeneous adoption patterns where advanced clinical centers often lead in implementing novel assays and decentralized testing, while other markets emphasize cost-effectiveness and scalability. Regulatory frameworks and reimbursement pathways vary widely across this combined region, which shapes commercialization timelines and clinical validation strategies. In the Asia-Pacific region, investment in local manufacturing capabilities and rapid adoption of point-of-care solutions are prominent, with several markets demonstrating aggressive uptake driven by high patient volumes and government-led diagnostics initiatives. Across all regions, companies that tailor deployment strategies to regional clinical practice, regulatory nuance, and supply chain realities will find the strongest pathways to sustainable adoption and collaboration.

Competitive and collaborative profiles that reveal how incumbent assay providers and nimble innovators deploy clinical evidence manufacturing and partnerships to capture diagnostic relevance

Competitive dynamics in cardiac biomarker diagnostics reflect both entrenched assay providers and agile innovators seeking clinical differentiation through improved analytics, workflow integration, and decentralized capabilities. Established players typically leverage broad distribution networks, long-standing clinical validation data, and integrated platforms to maintain trust among large health systems and reference laboratories. At the same time, smaller companies and new entrants concentrate on high-sensitivity assays, point-of-care instrumentation, and partnering with clinical trial networks to build evidence that supports adoption in acute and ambulatory settings.

Strategic alliances and OEM relationships continue to shape product availability and geographic reach. Forward-looking organizations invest in clinical partnerships that expedite real-world validation and in digital tools that enhance result interpretation. From an operational standpoint, companies that demonstrate robust quality systems, transparent supply chains, and rapid post-market support create competitive advantage. Consequently, effective strategies combine rigorous clinical evidence generation, scalable manufacturing approaches, and customer-centric service models to secure sustained adoption across diverse healthcare environments.

Actionable strategic imperatives for manufacturers laboratories and healthcare leaders to harmonize clinical validation supply resilience and digital integration for durable adoption

Industry leaders can accelerate value creation by aligning product roadmaps with clinical workflows and by strengthening supply chain resilience to withstand policy and logistic disruptions. Prioritizing interoperability with electronic health records and decision-support systems will reduce friction in clinical adoption and improve the actionable value of biomarker results. In addition, investing in clinical validation studies that demonstrate utility across key use cases-particularly acute coronary syndrome, congestive heart failure, and myocardial infarction pathways-will support broader clinician confidence and payer recognition.

Operationally, manufacturers and laboratory networks should diversify supplier relationships and consider regional manufacturing or contract manufacturing partnerships to reduce exposure to tariff-driven or logistical risks. Sales and medical affairs teams should build targeted outreach programs tailored to diagnostic laboratories, hospitals and clinics, and research institutes, emphasizing assay performance, workflow integration, and real-world evidence. Finally, embracing iterative product improvement through post-market surveillance and customer feedback loops will enable continuous refinement and stronger long-term partnerships with clinical stakeholders.

Transparent mixed-methods approach combining clinician interviews literature review regulatory analysis and scenario evaluation to ensure clinical and operational rigor in findings

The research behind this executive analysis combines multi-source evidence collection with structured qualitative and quantitative methods to ensure robust, reproducible findings. Primary research encompassed interviews with clinical laboratory directors, cardiology specialists, procurement leaders, and industry executives to capture contemporary perspectives on assay performance, workflow integration, and adoption barriers. Secondary research included peer-reviewed clinical literature, regulatory guidance documents, and publicly available clinical trial registries to corroborate clinical utility claims and analytical performance characteristics.

Data synthesis applied thematic analysis to primary interview transcripts and cross-validation against secondary sources to identify convergent trends and region-specific nuances. Supply chain and policy implications were evaluated through scenario analysis that considers alternative sourcing configurations and tariff impacts on procurement strategies. Throughout the methodology, emphasis remained on clinical relevance, operational feasibility, and regulatory context to produce insights that are both actionable and aligned with frontline decision-making requirements.

Concise synthesis of how clinical innovation supply chain resilience and targeted evidence strategies collectively determine success in cardiac biomarker deployment

In summary, cardiac biomarker diagnostics stand at a pivotal juncture where assay innovation, digital integration, and supply chain strategy converge to reshape clinical practice. High-sensitivity assays and decentralized testing models are redefining diagnostic timelines and enabling more responsive care pathways, while evolving trade dynamics underscore the importance of localized supply resilience and strategic partnerships. At the same time, segmentation-specific considerations across biomarker type, clinical setting, application, and end user highlight the necessity of tailored development and commercialization strategies.

Decision-makers should prioritize clinical evidence generation, interoperability, and operational agility to capture the full potential of biomarker-driven care. Firms that align technical innovation with pragmatic deployment strategies and that engage proactively with clinicians and laboratory leaders will be best positioned to convert scientific advances into improved patient outcomes. Ultimately, a disciplined, evidence-based approach to product development and market engagement will create enduring clinical value and competitive differentiation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac Biomarker Market, by Biomarker Type

  • 8.1. BNP & NT-proBNP
  • 8.2. Creatine Kinase (CK) MB
  • 8.3. Myoglobin
  • 8.4. Troponins

9. Cardiac Biomarker Market, by Clinical Setting

  • 9.1. Laboratory Testing
  • 9.2. Point Of Care Testing

10. Cardiac Biomarker Market, by Application

  • 10.1. Diagnosis
    • 10.1.1. Acute Coronary Syndrome
    • 10.1.2. Congestive Heart Failure
    • 10.1.3. Myocardial Infarction
  • 10.2. Prognosis
  • 10.3. Risk Assessment

11. Cardiac Biomarker Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals & Clinics
  • 11.3. Research Institutes

12. Cardiac Biomarker Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cardiac Biomarker Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cardiac Biomarker Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cardiac Biomarker Market

16. China Cardiac Biomarker Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Abcam plc
  • 17.7. Becton, Dickinson and Company
  • 17.8. Bio-Rad Laboratories Inc.
  • 17.9. bioMerieux SA
  • 17.10. Danaher Corporation
  • 17.11. DiaSorin S.p.A.
  • 17.12. Epitope Diagnostics Inc.
  • 17.13. F. Hoffmann-La Roche AG
  • 17.14. Fujirebio Diagnostics Inc.
  • 17.15. Guangzhou Wondfo Biotech Co., Ltd.
  • 17.16. Hologic Inc.
  • 17.17. Johnson & Johnson Services, Inc.
  • 17.18. Life Diagnostics, Inc.
  • 17.19. LSI Medience Corporation
  • 17.20. Meridian Bioscience, Inc.
  • 17.21. Myriad RBM Inc.
  • 17.22. PerkinElmer, Inc.
  • 17.23. Quest Diagnostics Incorporated
  • 17.24. Quidel Corporation
  • 17.25. QuidelOrtho Corporation
  • 17.26. Randox Laboratories Limited
  • 17.27. Sekisui Medical Co., Ltd.
  • 17.28. Siemens Healthineers AG
  • 17.29. Singulex, Inc.
  • 17.30. Sysmex Corporation
  • 17.31. Thermo Fisher Scientific Inc.
  • 17.32. Tosoh Corporation
  • 17.33. Trinity Biotech plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIAC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARDIAC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BNP & NT-PROBNP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BNP & NT-PROBNP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BNP & NT-PROBNP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CREATINE KINASE (CK) MB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CREATINE KINASE (CK) MB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CREATINE KINASE (CK) MB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY PROGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GCC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GCC CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 111. GCC CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. GCC CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 113. GCC CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. G7 CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. G7 CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 129. G7 CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. G7 CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 131. G7 CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NATO CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NATO CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NATO CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 135. NATO CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. NATO CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 137. NATO CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)